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Abstract 1 
Background: 2 
Around 10-15% of the inpatient population carry unsubstantiated ‘penicillin 3 
allergy’ labels, the majority incorrect when tested. These label are associated 4 
with harm, from use of broad-spectrum non-penicillin antibiotics.  Current 5 
testing guidelines incorporate both skin and challenge tests; this is 6 
prohibitively expensive and time-consuming to deliver on a large scale. We 7 
aimed to establish feasibility of a rapid access de-labelling pathway for surgical 8 
patients, using direct oral challenge. 9 
 10 
Methods 11 
‘Penicillin allergic’ patients, recruited from surgical pre-assessment clinic, were 12 
risk-stratified using a screening questionnaire. Patients at low risk of true, IgE-13 
mediated allergy were offered direct oral challenge, using incremental 14 
amoxicillin to a total dose 500mg. A 3-day course was completed at home. De-15 
labelled patients were followed up to determine antibiotic use in surgery, and 16 
attitudes towards de-labelling were explored. 17 
 18 
Results 19 
Of 219 patients screened, 74 were eligible for inclusion and offered testing. 20 
We subsequently tested 56 patients; 55 were de-labelled. None had a serious 21 
reaction to the supervised challenge, or thereafter. On follow-up, 17/19 22 
received appropriate antimicrobial prophylaxis during surgery. Only 3/33 de-23 
labelled patients would have been happy for the label to be removed without 24 
prior specialist testing. 25 
 26 
Conclusion 27 
Rapid access de-labelling, using direct oral challenge in appropriately risk-28 
stratified patients, can be incorporated into the existing surgical care pathway. 29 
This provides immediate, and potential long-term benefit for patients. Interest 30 
in testing is high among patients, and clinicians appear to follow clinic 31 
recommendations. Patients are unlikely to accept removal of their allergy label 32 
on the basis of history alone.  33 
 34 
Key words: penicillin; allergy; de-labelling; peri-operative. 35 
36 
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 3
An estimated 5-10% of people carry a label of penicillin allergy, 
(1, 2)
 with a 1 
higher incidence of around 15% observed in the inpatient population 
(2, 3)
. At 2 
least 92-95% of unsubstantiated penicillin allergy labels are incorrect when 3 
tested 
(4, 5)
with side effects and other non-allergic phenomena misattributed to 4 
allergy by patients, clinicians or both. It is now widely recognised that the 5 
‘penicillin allergic’ label is associated with increased morbidity, greater 6 
healthcare costs, increased rates of methicillin resistant Staphylococcus aureas 7 
(MRSA), Clostridium difficile and vancomycin resistant enteroccocus (VRE) 8 
infection, longer hospital stays, increased readmission rates, and more critical 9 
care admissions 
(2, 6-8)
.
 
This is most likely through the avoidance of ‘best first-10 
line’ antimicrobial therapy with penicillins, and use of broad-spectrum 11 
alternatives. In surgical patients, there is evidence of increased risk of wound 12 
infections when penicillins are replaced with non-beta lactam alternatives 
(9, 10)
 13 
and of peri-operative anaphylaxis from the alternatives used 
(11, 12)
  14 
Testing patients for penicillin allergy, according to current guidelines, is a 15 
relatively time-consuming and expensive process.
(13)
 As a result, it is generally 16 
only accessible to a minority of patients. In the UK, this is typically those in 17 
whom penicillin is the only therapeutic option or those likely to require 18 
multiple courses of antibiotics.
 (14)
 19 
In this study, we tested the feasibility of incorporating a rapid access, 20 
and abbreviated, de-labelling programme into the existing surgical care 21 
pathway. This involved a direct oral challenge, in patients identified as being at 22 
low risk of a true penicillin allergy. We assessed the acceptability of this 23 
intervention among patients and clinicians, and the impact on prescribing 24 
during their surgery.  25 
 26 
27 
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 4
Methods 1 
The study was approved by the Leeds East Research Ethics Committee (ref: 2 
17/YH/0096), and registered with ClinicalTrials.gov (protocol ID: AN17/92982). 3 
It took place in a single centre, tertiary care setting in the UK, between May 4 
2017 and June 2018.  5 
Patients were recruited by the surgical pre-assessment clinic nurses, 6 
who identified ‘penicillin allergic’ patients and administered a screening 7 
questionnaire. The questionnaire risk stratified them for likelihood of IgE-8 
mediated penicillin allergy, (see appendix 1), and also identified suitability for 9 
inclusion into the study.  See tables 1 and 2 for details of risk stratification and 10 
eligibility criteria.  Only a small proportion of pre-assessment nurses were 11 
trained to undertake this screening, so recruitment was undertaken on an ‘ad-12 
hoc’ basis, dependant on their availability 13 
Eligible patients attended a dedicated de-labelling clinic, where a direct 14 
oral challenge was performed using oral amoxicillin, after gaining written 15 
consent. The clinic had the facility to test for alternatives, should the index 16 
penicillin be different.  An incremental dosing regimen of 10%, 50%, 100% full 17 
dose (500mg) was used, with 20 minute intervals between doses. This is the 18 
protocol used for low risk patients who undergo challenge testing in the 19 
Immunology department in Leeds Teaching Hospitals. Patients were observed 20 
for a further one hour after the full dose, before being allowed home. Baseline 21 
blood pressure, heart rate and oxygen saturations were measured, but only 22 
repeated if the patient became unwell during testing. Full resuscitation 23 
equipment and personnel were immediately available.  24 
Challenge negative patients were given a 3-day course of antibiotic to 25 
complete at home, with an information sheet containing advice and contact 26 
details in the event of problems. The team contacted patients by telephone at 27 
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the end of the course, and checked for delayed symptoms. This was generally 1 
at a minimum of 5-7 days after the patient had left hospital. The results of 2 
testing were confirmed in writing to the patient, GP and surgeon, and the 3 
hospital electronic record updated accordingly. Feedback was sought during 4 
the phone consultation, on several aspects of the testing process.  5 
Where appropriate, notes were reviewed to determine which antibiotics 6 
had been administered for surgical prophylaxis. Three months after testing, 7 
the GP was contacted by telephone to check the patient’s allergy status on 8 
their primary care record. 9 
Midway through the study, the eligibility criteria were amended in 10 
response to high patient demand for testing (substantial amendment 11 
31/10/2017). From this point, all patients with low risk symptoms were offered 12 
testing, including those with r cent reactions (if symptoms were clearly 13 
remembered by the patient), those not requiring penicillin for surgery, and 14 
those who could only be tested post-operatively.  15 
 16 
 17 
  18 
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Results 1 
During the study period, a total of 219 patients with the ‘penicillin allergic’ 2 
label were screened. Of these, 74 patients were eligible for testing, and 145 3 
ineligible.  See Fig. 1 for outcome of screening for all patients. 4 
A total of 56 patients underwent a direct oral challenge. No patient 5 
suffered any immediate adverse reactions, and none suffered any serious 6 
delayed reactions subsequent to leaving hospital. One patient developed 7 
urticaria in her hands after the second dose and stopped taking the amoxicillin. 8 
On questioning, it was discovered that her index reaction had been of 9 
widespread urticaria, but she had chosen not to disclose this to the study team 10 
previously as she was keen to be tested. Four patients experienced mild non-11 
allergic symptoms during the prolonged antibiotic course. Two were 12 
considered to be unrelated to th  amoxicillin (sore throat and a cough in one 13 
patient, and a worsening of existing arthralgia in the other); another two 14 
experienced mild nausea. All four completed the course of antibiotic. 15 
Among patients who did not attend clinic (n=18), five were unable to attend 16 
because of ongoing illness and treatment, or a change of surgical date. The 17 
remainder simply did not turn up for their appointments. This was despite the 18 
study team attempting to contact all patients a few days ahead of the 19 
appointments to confirm attendance.  20 
A total of 119 patients had ‘low risk’ symptoms, described in Table 3. 21 
Not all of these were eligible for testing, however, as they did not meet other 22 
eligibility criteria. In around half, the reason for ineligibility was refusal to 23 
undergo testing; the remainder were ineligible because penicillin was not 24 
required, or the operation was too soon to have time to be tested. These 25 
eligibility criteria were removed midway through the study in response to high 26 
patient demand. One patient was ineligible due to high risk co-morbidities.  27 
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All screened patients were asked if they would like to undergo testing. 1 
Overall, 74% (163/219) stated they would like to be tested. Within the ‘low 2 
risk’ population 82% (98/119) requested testing; in the ‘high risk’ group 66% 3 
(59/90) requested it. In patients who declined testing (56), the reasons for this 4 
were explored (Fig. 2). There were 10 patients for whom no information was 5 
available except whether they would like to be tested; 6 of these wished to be 6 
tested. 7 
Among patients who were successfully de-labelled, feedback was sought 8 
on levels of satisfaction with the process. Although a majority stated they 9 
would have preferred testing to be performed on the same day as pre-10 
assessment (70%, 30/47), it was broadly considered to be a ‘smooth process’ 11 
(85%, 40/47). Low levels of anxiety about the testing were noted, with 81% 12 
(35/43) stating they had little or no anxiety on the day.  Patients were asked if 13 
they would have been happy for their label to be removed without any testing 14 
at all, on the basis that their index reaction did not indicate allergy. The 15 
majority, 70% (30/43) would not have been happy to have their allergy label 16 
removed in this way. Comments included: “The security of supervision takes 17 
away the anxiety”; “In case I had a bad reaction”; “I would worry about having 18 
a bad reaction without support, in case help was needed”, and “You can’t undo 19 
30 years of being allergic to penicillin with a quick conversation”.  20 
In the follow-up of patients subsequently undergoing surgery, 17/19 21 
were given appropriate penicillin-based surgical prophylaxis uneventfully; 22 
penicillin was avoided in two patients despite negative testing. In patients 23 
successfully de-labelled, the GP confirmed that the correct allergy status was 24 
present on the primary care record in 47/55 patients. The reason for re-25 
labelling in our current cohort is only known in one patient; this patient was 26 
discovered to have relabelled himself, when he was incidentally anaesthetised 27 
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for an emergency operation by a member of the study team. This patient’s 1 
recollection of the testing was that he had been told he had “suffered a severe 2 
allergic reaction and must continue to avoid penicillin at all costs”. Despite 3 
reassurance, he was adamant he would not wish to receive penicillin for 4 
surgery, and instead received teicoplanin. 5 
 6 
7 
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Discussion 1 
 2 
In this study, a rapid access and abbreviated de-labelling test was 3 
integrated into the existing pre-operative care pathway. Patients were risk 4 
stratified on the basis of history alone, and those at low-risk of IgE-mediated 5 
hypersensitivity, in whom skin testing was unlikely to offer additional 6 
diagnostic value, underwent a direct oral challenge test. Recall of exact timing 7 
of the index reaction by patients is accepted to be poor, especially when from 8 
many years ago.
(15)
 Instead, we focused on the symptoms of the reaction, and 9 
their severity. In particular, we asked about requirement for hospitalisation 10 
and treatment of the index event, as a marker of severity. None of the patients 11 
tested suffered serious adverse events during testing. This is consistent with 12 
the findings of similar studies, which demonstrate the safety of this approach 13 
when patients are appropriately risk stratified 
(16-18)
.  14 
 The incidence of unsubstantiated penicillin allergy labels in hospital 15 
inpatients is around 10-15%. As well as potential harm for individuals, there 16 
exists the wider problem of multi-resistant bacterial strains that are promoted 17 
by the use of broad-spectrum antibiotics, and an ever-decreasing pool of 18 
antimicrobial options to treat these. Improving stewardship through more 19 
rational antibiotic use, is a key strategy for healthcare systems
(19)
. Reducing the 20 
number of people inappropriately denied penicillin contributes to this, and 21 
novel strategies should be developed to allow wider access to de-labelling and 22 
promote effective use of penicillins where possible. 
(20)
 23 
Current guidelines advise that patients are referred to specialist services 24 
for testing. The gold standard test with which to establish tolerance to 25 
penicillin is a challenge, using the index penicillin to which the patient reacted. 26 
According to current UK and European guidelines, patients should first be skin 27 
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 10 
tested, using prick or intradermal tests, or both 
(1, 21, 22)
. This identifies patients 1 
who are IgE-sensitised, and provides risk stratification for progression to the 2 
next step in the diagnostic pathway, a challenge test.
(1, 21)
 Skin tests have a 3 
negative predictive value (NPV) approaching 100%, and patients who do not 4 
react to prick or intradermal tests are therefore unlikely to have a severe 5 
reaction on challenge. 
(5, 23)
 However the interpretation of positive skin tests is 6 
less clear; these patients are generally not offered a challenge test and so the 7 
positive predictive value (PPV) is hard to determine. The PPV is generally 8 
accepted to be less than 50% based on a limited numbers of prospective 9 
studies, and on outcomes from accidental re-exposure 
(24-26)
.  10 
There are significant limitations to skin testing. Many studies have 11 
commented on reduced sensitivity over time,
(3, 27, 28)
 and low sensitivity and 12 
specificity in patients with non-s vere, non-immediate, and vague reactions. 13 
(29-32)
 Reactions in childhood, typically delayed onset and unspecified rashes 14 
which can result in life long allergy labels, are only rarely associated with 15 
positive skin or challenge testing.
(33)
 16 
Increasingly, the evidence demonstrates that patients can be risk 17 
stratified for a challenge test on the basis of history alone. Where symptoms 18 
are not severe, not suggestive of an IgE-mediated reaction, are vague, or 19 
historic, the utility of skin testing is low and a direct oral challenge may be safe 20 
and appropriate. This approach is already used routinely for children in the UK, 21 
(34, 35)
 and several studies have demonstrated safety and efficacy in adults. 
(16-
22 
18).  
23 
A number of antimicrobial stewardship programmes have been 24 
successful at reducing the burden of unsubstantiated penicillin allergy labels, 25 
and have demonstrated benefits from doing so.
(10, 36-40)
 Some programmes 26 
have been used specifically in the pre-operative setting, with subsequent 27 
Page 10 of 21British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 11 
reduced use of intra-operative vancomycin and other beta-lactam alternatives. 1 
(41, 42)
 The majority of these programmes administer skin tests initially, and only 2 
proceed to challenge testing if these are negative. Whilst this is an accepted 3 
and valid strategy, the skin-testing component has implications for the overall 4 
cost and convenience of the pathway. Skin testing kits are relatively expensive 5 
and require trained personnel for their use and interpretation. There is also 6 
the potential for over-diagnosis due to false positive skin tests, and continued 7 
unnecessary avoidance of penicillin in such patients. The use of direct oral 8 
challenge in low risk patients is recent in Europe, but has been successfully 9 
employed in several centres in the US; this gap in practice has recently been 10 
commented
(43)
. 11 
Although not all labels can be removed using this pathway, we estimate 12 
from this study that at least one third of ‘penicillin allergic’ patients would be 13 
suitable for direct oral challenge. Patients with labels more suggestive of IgE-14 
mediated allergy continue to require skin testing as part of their diagnostic 15 
work-up, or should be advised to continue avoiding penicillins. Patients with 16 
histories of severe, widespread skin reactions, including delayed and blistering 17 
eruptions such as DRESS and TENS, are also high risk and must avoid penicillin.  18 
The barriers to implementing this on a large scale are two-fold; human 19 
factors leading to anxiety around allergy labels, and financial implications. We 20 
were able to explore some of the human factors in this study.  21 
The first perceived barrier was a lack of interest in testing. However, 22 
patients appeared keen to be tested, irrespective of the severity of their 23 
presenting symptoms.  The change to our eligibility criteria was indeed made 24 
in direct response to demand among patients with low risk labels, but who 25 
were ineligible for other reasons - most commonly lack of time, or lack of 26 
immediate need for penicillin.  27 
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 12 
A second potential barrier was lack of acceptance among clinicians 1 
(primarily anaesthetists) that the abbreviated pathway provided conclusive 2 
evidence of tolerance to penicillin. However, clinic advice was generally 3 
accepted by anaesthetists on the day of surgery. In the two patients denied 4 
penicillin peri-operatively, it is not known whether the anaesthetist actively 5 
disregarded the test result or was simply unaware of it.  6 
Lastly, it has been demonstrated previously that a high proportion of 7 
patients re-label themselves following negative testing for penicillin allergy, or 8 
are re-labelled by healthcare providers.
(44)
 However, the rate of ‘re-labelling’ in 9 
our population appeared to be very low. Only the longer term follow-up of this 10 
cohort will determine whether this is indeed true. It is likely that behavioural 11 
change interventions will be required in addition to the de-labelling itself, in 12 
order to address this issue. Th re is little literature in this field to date, 13 
although one centre in the US has used pharmacist counselling and wallet-14 
cards with confirmation of test results, to good effect.
(45)
 15 
The financial barrier to widespread testing is likely to be significant. 16 
Although long term cost benefits are likely to be realised through de-labelling 17 
patients, there is an ‘upfront’ cost to perform the testing. Omitting skin tests 18 
helps with this, but even abbreviated pathways using direct oral challenge 19 
have a cost attached, which is not immediately offset by the avoidance of a 20 
single intra-operative dose of a more expensive alternative antibiotic.  21 
Finally, this study addressed the question of acceptability of de-labelling 22 
without formal testing; i.e. on the basis of history alone. In those with histories 23 
clearly consistent with side effects (eg nausea, or thrush), those who have 24 
received penicillin uneventfully since their index reaction, and those with only 25 
a family history of allergy, there is no requirement for allergy testing. In the 26 
authors’ institution, guidelines recommend that penicillin can be administered 27 
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without prior testing in such patients, although these are rarely followed. Our 1 
results indicate that patients may be reluctant to receive penicillin without 2 
formal testing under supervision.  3 
The limitation of this study is primarily its small size, and further work is 4 
needed to corroborate our findings. In addition, we only have follow up data 5 
from three months post-testing. It would be informative to identify the rate of 6 
re-labelling several years after testing, and explore the reasons for this. 7 
Nevertheless, our results are encouraging in terms of potential uptake in 8 
future studies. Based on our work, uptake could be maximised by offering 9 
‘opportunistic’ testing of all patients attending for surgical pre-assessment 10 
irrespective of the need for penicillin during surgery, offering testing as part of 11 
the initial pre-assessment visit rather than a separate clinic appointment, and 12 
reducing the time required for testing. The last of these could be achieved by 13 
moving from an incremental, to single dose challenge, using 250 or 500mg 14 
amoxicillin. The utility of this has been confirmed in a study of 500 sequential 15 
patients in the US,
(4)
 and a cohort of Marine recruits also in the US, 
(18)
 where 16 
low risk patients received a single dose oral challenge with none having a 17 
severe life threatening reaction. Using this protocol, the time for testing would 18 
be reduced from one hour 45, to around one hour, increasing both the 19 
likelihood of uptake among patients, and  the turnover in clinic. In the last few 20 
months of this study, the protocol was altered to allow single dose challenge 21 
(substantial amendment 5/1/18), although none received this before the end 22 
of the study period. A single dose approach will be taken in future de-labelling 23 
programs at the host site. 24 
It is increasingly clear that the burden of ‘en masse’ de-labelling cannot 25 
be shouldered by specialist services in isolation, since these are relatively small 26 
groups with already scarce resources. Our protocol is one example of how 27 
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 14 
testing might be integrated into an existing patient pathway, and delivered by 1 
non-specialists working in close collaboration with allergy/immunology 2 
specialists.  3 
 4 
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Table 1: Definition of ‘high risk’ and ‘low risk’ symptoms.  1 
‘LOW RISK’ SYMPTOMS ‘HIGH RISK’ SYMPTOMS 
Nausea, vomiting, diarrhoea Anaphylaxis 
Non-itchy rash Angioedema 
Thrush Swelling of face/body 
Not admitted to hospital Severe blistering skin rash 
‘Don’t know/can’t remember  Wheeze, shortness of breath 
 Collapse or dizziness 
 Itchy rash 
 Symptoms required hospital admission and 
treatment 
 2 
 3 
Table 2 – Eligibility criteria 4 
ELIGIBLE INELIGIBLE 
Low risk symptoms High risk symptoms 
Reaction occurred > 15 years ago
* 
Reaction < 15 years ago 
Sufficient time for testing pre-operatively
* 
No time for testing 
Wants to be tested Declines testing 
Requires penicillin for surgery
* 
Doesn’t require penicillin for surgery 
Aged >18 years Pregnant, breastfeeding 
 Unstable asthma (oral steroids 
required in the last 6 months) 
 *These three criteria were amended following high demand for testing amongst otherwise eligible patients. 5 
 6 
 7 
 8 
 9 
 10 
 11 
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Table 3: Symptoms of Index Reaction in 119 Low Risk Group 1 
SYMPTOM GI
*
 UPSET RED RASH 
FLUSHING 
RASH  
(UNSPECIFIED) 
DON’T KNOW 
CAN’T REMEMBER 
THRUSH MISCELLANEOUS 
(EG ‘CONVULSIONS’) 
N  32 41 25 41 1 2 
* Gastrointestinal; GI. NB Total number of symptoms exceeds 119 as some patients had more than 1 symptom 2 
 3 
 4 
 5 
Fig 1. Outcomes of All Screened Patients 6 
Fig 2. Reasons why patients with a label of ‘penicillin allergy’ declined testing 7 
 8 
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Figure1. Outcomes of All Screened Patients  
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Figure 2.Reasons why patients with a label of ‘penicillin allergy’ declined testing 
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